Specifically, we focused on four previously-studied, targeted anti-cancer drugs for which our model includes primary targets and significant off-targets: trametinib (MEK inhibitor), alpelisib (PI-3Kα inhibitor), neratinib (EGFR/ErbB2/ErbB4 inhibitor), and palbociclib (CDK4/6 inhibitor) [55]. This evidence concerns the gene MAP2K7 and cancer.